Review Article

High Blood Pressure & Cardiovascular Prevention

, Volume 12, Issue 3, pp 119-124

First online:

Antihypertensive Drugs and Coronary Artery Disease

Evidence from Controlled Trials
  • Paolo VerdecchiaAffiliated withDipartimento Malattie Cardiovascolari, Ospedale R. Silvestrini Email author 
  • , Fabio AngeliAffiliated withDipartimento Malattie Cardiovascolari, Ospedale R. Silvestrini

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


A reduction in blood pressure (BP) levels is the most important mechanism accounting for the reduction in cardiovascular complications induced by treatment. However, results of recent clinical trials and meta-analyses have shown that antihypertensive drugs possess important ancillary properties that might play an additional role in the prevention of cardiovascular disease.

Reviewing the literature, ACE inhibitors seem to have ancillary properties that can contribute to influence the risk of coronary artery disease with mechanisms partially independent of BP reduction.

On the other hand, dihydropyridine calcium channel blockers, such as amlodipine, have been proven to lower the incidence of stroke but their use seems to be effective in relieving symptoms of coronary artery disease and reducing the rate of revascularisation procedures.